Literature DB >> 34373668

Current and Future Immunotherapies for Multiple Sclerosis.

Jessica Bourque1, Daniel Hawiger1.   

Abstract

Despite substantial progress in developing new immunotherapies against multiple sclerosis (MS), currently available immunotherapies are only partially effective for this debilitating neurological disease, thus necessitating new therapeutic approaches. Here, we review the immunotherapies already approved for MS as well as relevant clinical trials. Further, we present some experimental approaches that are currently being developed and are focused on modulating the functions of dendritic cells and regulatory T cells. Copyright 2021 by the Missouri State Medical Association.

Entities:  

Year:  2021        PMID: 34373668      PMCID: PMC8343631     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  4 in total

Review 1.  Variegated Outcomes of T Cell Activation by Dendritic Cells in the Steady State.

Authors:  Jessica Bourque; Daniel Hawiger
Journal:  J Immunol       Date:  2022-02-01       Impact factor: 5.426

Review 2.  Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo.

Authors:  Jessica Bourque; Daniel Hawiger
Journal:  Antibodies (Basel)       Date:  2022-01-25

3.  TnP Peptide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) in a Preclinical Mouse Model.

Authors:  Carla Lima; Adolfo Luis Almeida Maleski; Jefferson Thiago Gonçalves Bernardo; Vitor Cataldi Zelli; Evilin Naname Komegae; Monica Lopes-Ferreira
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

4.  Shedding Light on the Drug-Target Prediction of the Anti-Inflammatory Peptide TnP with Bioinformatics Tools.

Authors:  Carla Lima; Silas Fernandes Eto; Monica Lopes-Ferreira
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.